Evidence map›Paper›PMID 30121654›Full record

ArticleCardiorenal medicine2018

Urine Cofilin-1 Detection for Predicting Type 1 Cardiorenal Syndrome in the Coronary Care Unit: A Gold Nanoparticle- and Laser-Based Approach.

Hsing-Yu Chen, Chien Chou, Chih-Hsiang Chang, Nien-Gen Lee, Pei-Chun Yu, Yu-Chi Chen, Heng-Chih Pan, Pei-Chun Fan, Chih-Wei Yang, Wen-Jin Cherng and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiorenal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Hsing-Yu ChenGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chien ChouGraduate Institute of Electro-Optical Engineering, Chang Gung University, Taoyuan, Taiwan.
Chih-Hsiang ChangGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Nien-Gen LeeGraduate Institute of Electro-Optical Engineering, Chang Gung University, Taoyuan, Taiwan.
Pei-Chun YuGraduate Institute of Electro-Optical Engineering, Chang Gung University, Taoyuan, Taiwan.
Yu-Chi ChenGraduate Institute of Electro-Optical Engineering, Chang Gung University, Taoyuan, Taiwan.
Heng-Chih PanDivision of Nephrology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan.
Pei-Chun FanGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chih-Wei YangKidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Linkou, Taiwan.
Wen-Jin CherngCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Yung-Chang ChenCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chang Gung Memorial Hospital · TWChang Gung University · TWKeelung Chang Gung Memorial Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 1 cardiorenal syndrome (CRS) is a severe complication for acute decompensated heart failure patients. This study aimed at evaluating the feasibility of using the gold nanoparticle-based localized surface plasmon-coupled fluorescence biosensor (LSPCFB) to detect urine cofilin-1 as a biomarker for predicting CRS among patients in the coronary care unit (CCU).

methodsA total of 44 patients were included with prospectively collected urine and blood samples. Both LSPCFB and conventional enzyme-linked immunosorbent assays (ELISAs) were used to measure urine cofilin-1 at admission to the CCU. The occurrence of CRS was judged within 7 days after admission. The discrimination presented as the area under the receiver operating characteristic curve (AUROC) and calibration of both detection methods were used to assess the predictive ability of urine cofilin-1 measured by the LSPCFB and ELISA.

resultsThirteen patients were diagnosed with CRS, while the other 31 patients were classified into a non-CRS group. For predicting CRS by measuring urine cofilin-1, the LSPCFB had higher accuracy (AUROC: 0.707, p = 0.031; overall accuracy: 79.55%) than the ELISA (AUROC: 0.479, p = 0.827; overall accuracy: 53.27%). The positive and negative predictive values of the LSPCFB were also higher than those of the ELISA (positive predictive value: 70.0 vs. 34.8%; negative predictive value: 82.4 vs. 76.2%).

conclusionsThe gold nanoparticle-based immunoassay LSPCFB could exploit the potential of urine cofilin-1 as a single biomarker to predict CRS among CCU patients.

Indexed as

GoldLasersMetal NanoparticlesAgedBiomarkersCardio-Renal SyndromeCofilin 1Enzyme-Linked Immunosorbent AssayFeasibility StudiesFemaleHumansMaleMiddle AgedProspective StudiesSurface Plasmon ResonanceBiomarkersCFL1 protein, humanCofilin 1GoldAcute kidney injuryCardiorenal syndromeEnzyme-linked immunosorbent assayHeart failureLocalized surface plasmon-coupled fluorescence biosensor

Identifiers

PMID30121654
PMCPMC6477519
OpenAlexW2885196007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.